This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merit Medical (MMSI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Canopy Growth (CGC) to Report in Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.
Are Investors Undervaluing Henry Schein (HSIC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is a Beat in the Cards for CVS Health (CVS) in Q2 Earnings?
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital approach to administer vaccines across the nation is expected to have strongly contributed to its Q2 performance within retail segment.
Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q1 sales.
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the second quarter despite ongoing pandemic-led higher PPE costs.
Is a Beat in Store for Zimmer Biomet (ZBH) in Q2 Earnings?
by Zacks Equity Research
Zimmer Biomet's (ZBH) S.E.T. is expected to have performed better than expected on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.
What's in Store for Henry Schein (HSIC) in Q2 Earnings?
by Zacks Equity Research
Henry Schein's (HSIC) PPE sales from medical business are likely to have maintained momentum in Q2. Also, global recovery trends of its dental business are expected to reflect on Q2 results.
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Acquisitions of Cantel Medical and Key Surgical are expected to have contributed significantly to STERIS' (STE) first-quarter revenues.
What's in Store for IDEXX Laboratories (IDXX) in Q2 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) fiscal second-quarter top line is expected to have benefited from strength in CAG and LPD businesses.
Catalent (CTLT) Boosts Portfolio Via Launch of GPEx Lightning
by Zacks Equity Research
Catalent's (CTLT) latest product is aimed at improving customer service by speeding up the drug substance development process.
Breast Health Sales to Aid Hologic's (HOLX) Q3 Earnings
by Zacks Equity Research
The acquisition of Biotheranostics and relaunch of Brevera are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the third quarter.
What's in Store for Edwards Lifesciences (EW) Q2 Earnings?
by Zacks Equity Research
Continued adoption of TruWave disposable pressure monitoring devices and progress in transfemoral EVOQUE and SAPIEN M3 platforms are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.
PacBio (PACB) Enhances Sequencing Platform Via Latest Buyout
by Zacks Equity Research
PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Improvement in demand at non-COVID business and continued strength in Bio-Rad's (BIO) Life Science segment are likely to have contributed to Q2 results.
Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued strength in the Global Healthcare and Life Sciences segment.
Align Technology (ALGN) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Continued adoption of Invisalign Clear Aligners and iTero scanners are expected to have contributed to the Align Technology's (ALGN) second-quarter 2021 results.
Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its third-quarter performance.
HSIC vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. COO: Which Stock Is the Better Value Option?
Nevro's (NVRO) Senza System Approved by FDA for PDN Treatment
by Zacks Equity Research
Nevro's (NVRO) 10 kHz SCS treatment, which has received the FDA nod for treating patients with PDN, is expected to provide sustained pain relief as well as improve health-related quality of life.
Boston Scientific (BSX) Watchman FLX Sales to Aid Q2 Earnings
by Zacks Equity Research
Strong procedure recovery and market share gains across many of the businesses and regions are expected to have boosted Boston Scientific's (BSX) Q2 sales.
Nevro (NVRO) Reports Impressive Preliminary Q2 Revenues
by Zacks Equity Research
Improvement in Nevro's (NVRO) second-quarter revenues is likely to have resulted from a solid product portfolio.
Masimo (MASI) Boosts Its Product Suite With Latest Release
by Zacks Equity Research
Masimo's (MASI) latest offering is expected to improve patient care due to its re-engineered integration design.
Cerner (CERN) Extends Partnership to Accelerate Digital Health
by Zacks Equity Research
Cerner (CERN) expands its partnership with Baystate Health by launching a digital health platform to boost consumer-focused care.
Cardinal Health (CAH) Introduces 2 New Digital Solutions
by Zacks Equity Research
Cardinal Health (CAH) launches NavixRx Compliance Packaging and E-Commerce Storefront to allow independent pharmacists to expand services and support medication adherence.